BPC-157 10mg – Peptide Producer
US$ 26.00
bpc-157 tendon-to-bone healing animal studies Frontiers Application of peptide therapy for
Description
First-pass hepatic metabolism degrades an estimated 6085% of the compound before systemic circulation, requiring oral doses 35 times higher than parenteral routes to achieve comparable plasma concentrations
Numerous signaling pathways, such as cyclooxygenase 2 (COX-2), mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK) signaling, phosphoinositide 3 kinase (PI3K), and the GATA4/p62-mediated autophagy pathways result in the stimulation of NF-B and/or C/EBP pathways, which in turn regulate the SASP secretome (81, 82)
Maintenance phase (post week 8)
Bahn RS, Heufelder AE
